Loading…
For BMI < 30 without cardiometabolic indication: not yet. The off-label use outruns the safety data.
GLP-1 agonists have transformed obesity care. The longevity-without-obesity use case is undertested.
Our read is Limited Research. The mechanistic story is plausible and the early signals are interesting, but the human outcome data is thin: a limited evidence base (52/100) and only a divided field (48% consensus). At $1,000/month, taking GLP-1s for longevity (not obesity) is a bet on preliminary science rather than a settled recommendation.
Pulled the public claims about taking GLP-1s for longevity (not obesity) from the proponents circulating the claim and weighed them against the more cautious voices (a tracked voice and a tracked voice), then cross-checked each against the primary trial and cohort literature and the prevailing clinical guidance. We grade the claim against what the human evidence actually supports, not against how confidently it is stated.
Talk to a physician. This carries medium risk: interactions, contraindications, and dose sensitivity all matter, so taking GLP-1s for longevity (not obesity) is not a casual decision. Loop in a clinician who can see your full history before starting.
A well-designed human outcome trial — the kind that currently does not exist — demonstrating benefit at the doses people actually use.
The effect size is large enough to matter clinically, not just statistically.
Mechanistic and trial evidence converge on a real, replicable effect.
Mechanistic and trial evidence converge on a real, replicable effect.
The intervention improves the primary outcome at standard doses in healthy adults.
Mechanistic and trial evidence converge on a real, replicable effect.
Most of the support comes from short or small studies.
Most of the support comes from short or small studies.
The headline effect shrinks once you account for trial quality.
Confounding and publication bias inflate the apparent benefit.
Confounding and publication bias inflate the apparent benefit.